Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma LF Porrata1, KM Ristow1, TM Habermann1, WR Macon2, TE Witzig1, JP Colgan1, DJ Inwards1, SM Ansell1, IN Micallef1, PB Johnston1, G Nowakowski1, CA Thompson1 and SN Markovic1 The peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis (ALC/AMC-DX) predicts survival in classical Hodgkin lymphoma (cHL). However, a limitation of the ALC/AMC-DX is the inability to assess sequentially the host/tumor interaction during treatment. Therefore, we retrospectively examined the ALC/AMC ratio, as a surrogate marker of host immunity (ALC) and tumor microenvironment (AMC), at each adriamycin, bleomycin, vinblastine and dacarbazine treatment cycle as a predictor for clinical outcomes. From 1990 until 2008, 190 cHL patients were diagnosed, treated and followed at Mayo Clinic Rochester and qualified for the study. The ALC/AMC ratio at each treatment cycle was a predictor for overall survival (OS) and progression-free survival (PFS). An ALC/AMC ratio >1.1 versus ALC/AMC <1.1 during treatment cycles was an independent predictor for OS (hazard ratio (HR)=0.14; 95% confidence interval (CI): 0.04-0.40; P<0.0002) and for PFS (HR=0.19; 95% CI: 0.05-0.82; P<0.03). The ALC/AMC ratio during treatment cycles is a predictor for survival and provides a platform to develop therapeutic modalities to manipulate the ALC/AMC ratio during chemotherapy to improve clinical outcomes in cHL.

Original languageEnglish (US)
Article numbere110
JournalBlood Cancer Journal
Volume3
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Tumor Microenvironment
Hodgkin Disease
Monocytes
Lymphocytes
Therapeutics
Survival
Disease-Free Survival
Confidence Intervals
Dacarbazine
Vinblastine
Bleomycin
Lymphocyte Count
Doxorubicin
Immunity
Biomarkers
Drug Therapy

Keywords

  • ABVD chemotherapy
  • Classical Hodgkin lymphoma
  • Survival ALC/AMC ratio

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{658fcd92bf91489bbd7eda791689d368,
title = "Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma",
abstract = "Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma LF Porrata1, KM Ristow1, TM Habermann1, WR Macon2, TE Witzig1, JP Colgan1, DJ Inwards1, SM Ansell1, IN Micallef1, PB Johnston1, G Nowakowski1, CA Thompson1 and SN Markovic1 The peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis (ALC/AMC-DX) predicts survival in classical Hodgkin lymphoma (cHL). However, a limitation of the ALC/AMC-DX is the inability to assess sequentially the host/tumor interaction during treatment. Therefore, we retrospectively examined the ALC/AMC ratio, as a surrogate marker of host immunity (ALC) and tumor microenvironment (AMC), at each adriamycin, bleomycin, vinblastine and dacarbazine treatment cycle as a predictor for clinical outcomes. From 1990 until 2008, 190 cHL patients were diagnosed, treated and followed at Mayo Clinic Rochester and qualified for the study. The ALC/AMC ratio at each treatment cycle was a predictor for overall survival (OS) and progression-free survival (PFS). An ALC/AMC ratio >1.1 versus ALC/AMC <1.1 during treatment cycles was an independent predictor for OS (hazard ratio (HR)=0.14; 95{\%} confidence interval (CI): 0.04-0.40; P<0.0002) and for PFS (HR=0.19; 95{\%} CI: 0.05-0.82; P<0.03). The ALC/AMC ratio during treatment cycles is a predictor for survival and provides a platform to develop therapeutic modalities to manipulate the ALC/AMC ratio during chemotherapy to improve clinical outcomes in cHL.",
keywords = "ABVD chemotherapy, Classical Hodgkin lymphoma, Survival ALC/AMC ratio",
author = "Porrata, {L. F.} and Ristow, {K. M.} and Habermann, {Thomas Matthew} and Macon, {W. R.} and Witzig, {Thomas Elmer} and Colgan, {J. P.} and Inwards, {D. J.} and Ansell, {Stephen Maxted} and Ivana Micallef and Johnston, {Patrick Bruce} and Nowakowski, {Grzegorz S} and Thompson, {Carrie A} and Markovic, {Svetomir Nenad}",
year = "2013",
month = "4",
doi = "10.1038/bcj.2013.8",
language = "English (US)",
volume = "3",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

AU - Porrata, L. F.

AU - Ristow, K. M.

AU - Habermann, Thomas Matthew

AU - Macon, W. R.

AU - Witzig, Thomas Elmer

AU - Colgan, J. P.

AU - Inwards, D. J.

AU - Ansell, Stephen Maxted

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Nowakowski, Grzegorz S

AU - Thompson, Carrie A

AU - Markovic, Svetomir Nenad

PY - 2013/4

Y1 - 2013/4

N2 - Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma LF Porrata1, KM Ristow1, TM Habermann1, WR Macon2, TE Witzig1, JP Colgan1, DJ Inwards1, SM Ansell1, IN Micallef1, PB Johnston1, G Nowakowski1, CA Thompson1 and SN Markovic1 The peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis (ALC/AMC-DX) predicts survival in classical Hodgkin lymphoma (cHL). However, a limitation of the ALC/AMC-DX is the inability to assess sequentially the host/tumor interaction during treatment. Therefore, we retrospectively examined the ALC/AMC ratio, as a surrogate marker of host immunity (ALC) and tumor microenvironment (AMC), at each adriamycin, bleomycin, vinblastine and dacarbazine treatment cycle as a predictor for clinical outcomes. From 1990 until 2008, 190 cHL patients were diagnosed, treated and followed at Mayo Clinic Rochester and qualified for the study. The ALC/AMC ratio at each treatment cycle was a predictor for overall survival (OS) and progression-free survival (PFS). An ALC/AMC ratio >1.1 versus ALC/AMC <1.1 during treatment cycles was an independent predictor for OS (hazard ratio (HR)=0.14; 95% confidence interval (CI): 0.04-0.40; P<0.0002) and for PFS (HR=0.19; 95% CI: 0.05-0.82; P<0.03). The ALC/AMC ratio during treatment cycles is a predictor for survival and provides a platform to develop therapeutic modalities to manipulate the ALC/AMC ratio during chemotherapy to improve clinical outcomes in cHL.

AB - Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma LF Porrata1, KM Ristow1, TM Habermann1, WR Macon2, TE Witzig1, JP Colgan1, DJ Inwards1, SM Ansell1, IN Micallef1, PB Johnston1, G Nowakowski1, CA Thompson1 and SN Markovic1 The peripheral blood absolute lymphocyte/monocyte count ratio at diagnosis (ALC/AMC-DX) predicts survival in classical Hodgkin lymphoma (cHL). However, a limitation of the ALC/AMC-DX is the inability to assess sequentially the host/tumor interaction during treatment. Therefore, we retrospectively examined the ALC/AMC ratio, as a surrogate marker of host immunity (ALC) and tumor microenvironment (AMC), at each adriamycin, bleomycin, vinblastine and dacarbazine treatment cycle as a predictor for clinical outcomes. From 1990 until 2008, 190 cHL patients were diagnosed, treated and followed at Mayo Clinic Rochester and qualified for the study. The ALC/AMC ratio at each treatment cycle was a predictor for overall survival (OS) and progression-free survival (PFS). An ALC/AMC ratio >1.1 versus ALC/AMC <1.1 during treatment cycles was an independent predictor for OS (hazard ratio (HR)=0.14; 95% confidence interval (CI): 0.04-0.40; P<0.0002) and for PFS (HR=0.19; 95% CI: 0.05-0.82; P<0.03). The ALC/AMC ratio during treatment cycles is a predictor for survival and provides a platform to develop therapeutic modalities to manipulate the ALC/AMC ratio during chemotherapy to improve clinical outcomes in cHL.

KW - ABVD chemotherapy

KW - Classical Hodgkin lymphoma

KW - Survival ALC/AMC ratio

UR - http://www.scopus.com/inward/record.url?scp=84878321704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878321704&partnerID=8YFLogxK

U2 - 10.1038/bcj.2013.8

DO - 10.1038/bcj.2013.8

M3 - Article

C2 - 23599022

AN - SCOPUS:84878321704

VL - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 4

M1 - e110

ER -